AASLD 2022

News

Hepatitis Treatments Underutilized Among ‘Sickest’ With Liver Cancer

January 19, 2024
Alex Briese

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.

Read More

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also include acute flares and extrahepatic manifestations. In addition, people living with HBV infection also experience stigma. read more

Treatment for hepatitis C remains low, despite success

December 13, 2022 - By Emily Moskal

Antiviral treatment reduces complications of hepatitis C infection, but only two out of every three patients diagnosed with the virus receive the treatment, according to two recent studies led by Mindie Nguyen, MD, professor of gastroenterology and hepatology.

“I’m hoping the data will bring home the magnitude of the problems,” said Nguyen, the senior author of both papers. “The benefits are clearly shown in our study. We are looking at a population with probably better coverage than anyone — patients in the United States with private insurance — yet less than 65% of people diagnosed with hepatitis C received treatment. That is quite sobering.”

DAAs with, without PIs yield similar outcomes in decompensated HCV cirrhosis

AN DIEGO — Researchers reported similar clinical outcomes in patients with decompensated hepatitis C virus cirrhosis treated with direct-acting antivirals, with or without protease inhibitors, according to study results. See More

PI-based DAAs appear safe in decompensated patients

AT DDW 2022

SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompensation. See More

 

Using data from a US population-based epidemiology survey, the authors of this article found that people born after 1991 had better hepatitis B vaccination effectiveness and vaccinated individuals had lower all-cause and cancer-related mortality. see more

Therapy Slices HCC Risk in HBV's Indeterminate Phase 

AASLD-The Liver Meeting, November 4-8, 2022, Washington, DC
Mark Mascolini
Antiviral therapy for chronic hepatitis B virus (HBV) infection in the indeterminate phase sliced HCC risk by 70% through 15 years of follow-up [1]. Researchers from the National University of Singapore and REAL-B Consortium colleagues across the world believe their findings may support expansion of chronic HBV treatment criteria. see more